Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Vincerx Pharma (NASDAQ:VINC - Free Report) in a research report released on Monday morning, Benzinga reports.

Vincerx Pharma Stock Up 15.6 %

Shares of NASDAQ:VINC traded up $0.79 during midday trading on Monday, hitting $5.85. 939,944 shares of the stock traded hands, compared to its average volume of 1,092,049. The stock has a market capitalization of $125.07 million, a PE ratio of -2.29 and a beta of 1.09. The business's 50 day moving average is $3.66 and its two-hundred day moving average is $1.88. Vincerx Pharma has a one year low of $0.61 and a one year high of $9.37.

Hedge Funds Weigh In On Vincerx Pharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers purchased a new position in shares of Vincerx Pharma during the first quarter valued at about $53,000. Susquehanna International Group LLP purchased a new stake in Vincerx Pharma in the first quarter worth about $28,000. Goldman Sachs Group Inc. purchased a new stake in Vincerx Pharma in the first quarter worth about $119,000. Bank of Montreal Can purchased a new stake in Vincerx Pharma in the first quarter worth about $332,000. Finally, ExodusPoint Capital Management LP purchased a new stake in Vincerx Pharma in the second quarter worth about $132,000. 44.02% of the stock is owned by institutional investors.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.